In a report published Friday, Canaccord Genuity reiterated its Buy rating on Hi-Tech Pharmacal Co. (NASDAQ: HITK ), but lowered its price target from $42.00 to $40.00. Canaccord Genuity noted, “HITK reported F3Q results that brought some cough-and-cold-driven revenue upside that was appropriately overshadowed by the cost-driven EPS miss. While